InvestorsHub Logo
Followers 85
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: None

Thursday, 09/17/2015 3:38:08 PM

Thursday, September 17, 2015 3:38:08 PM

Post# of 346182
looks like Gerald Finken from CSM had just as much incentive to close out this lawsuit with Peregrine as well...

http://www.geraldfinken.com/improving-clinical-trials-with-patient-centric-care?gclid=CM7u3L_o_scCFUiRHwodb5EEJg

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!